- Home
- TROO vs IPHA Comparison
TROO vs IPHA Comparison
Compare TROO & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TROO | IPHA |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | Hong Kong | France |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.5M | 174.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | TROO | IPHA |
|---|---|---|
| Price | $1.93 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 93.3K | 26.6K |
| Earning Date | 12-04-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,084,000.00 | $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | N/A | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 247.24 | N/A |
| 52 Week Low | $0.49 | $1.60 |
| 52 Week High | $2.62 | $2.63 |
Technical Indicators
Market Signals| Indicator | TROO | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 67.65 | 36.12 |
| Support Level | $1.82 | $1.64 |
| Resistance Level | $2.27 | $1.81 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 59.56 | 22.58 |
Price Performance
Historical ComparisonAbout TROO TROOPS Inc.
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.